Who is sponsoring NCT01227252?

NCT01227252 is sponsored by Eli Lilly and Company.

What condition does NCT01227252 study?

NCT01227252 studies Alzheimer's Disease.

What drugs are being tested in NCT01227252?

Interventions: LY2886721, Placebo.

What is the status of NCT01227252?

NCT01227252 is currently COMPLETED.

Last reviewed 2019-05-09 · How we verify

Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects

NCT01227252 Phase 1 COMPLETED Results posted

This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 multiple doses, how the body handles the drug, and the drug's effect on the body.

Details

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	COMPLETED
Enrolment	42
Start date	2010-12
Completion	2011-04

Conditions

Alzheimer's Disease

Interventions

LY2886721
Placebo

Primary outcomes

Number of Participants With Clinically Significant Effects — Predose up to Day 70
Clinically significant effects were defined as serious and nonserious adverse events. A summary of serious and all other nonserious adverse events is located in the Reported Adverse Event module. The number of participants with at least 1 adverse event in each treatment arm is reported for this outcome measure.

Countries

United States